Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SHELL PLC1ST QUARTER 2022 UNAUDITED RESULTS SUMMARY OF UNAUDITED RESULTSQuarters$ million Q1 2022Q4 2021Q1...
-
Announcement no. 7 2022 Agillic continues double-digit growth with 26% increase in total ARR for Q1 2022 Copenhagen – 5 May 2022 - Agillic A/S (Nasdaq First North Growth Market Denmark: AGILC)...
-
To Nasdaq Copenhagen A/Sand the press5 May 2022 Nykredit today raises its profit guidance and announces Q1 Interim Report 2022 of: Nykredit A/S, CVR no 12 71 92 48Nykredit Realkredit A/S, CVR no 12...
-
To Nasdaq Copenhagen A/Sand the press5 May 2022 Nykredit today raises its profit guidance and announces Q1 Interim Report 2022 of: Nykredit A/S, CVR no 12 71 92 48Nykredit Realkredit A/S, CVR no...
-
May 05, 2022 FIRST QUARTER 2022Postive EBITDA at 221 million euros, better than expectedStrong adjusted operating free cash flow at 630 million eurosthanks to outstanding sales in March First quarter:...
-
Luxembourg, May 5, 2022 - ArcelorMittal (referred to as “ArcelorMittal” or the “Company”), (MT (New York, Amsterdam, Paris, Luxembourg), MTS (Madrid)), the world’s leading integrated steel and mining...
-
$21.2 million in VYVGART® (efgartigimod alfa-fcab) net product sales during initial quarter of U.S. commercial launchMet primary endpoint in Phase 3 ADVANCE trial of VYVGART for treatment of primary...
-
Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo (p=0.0316); responders observed across patient types...
-
COMMENTARY FROM MANAGEMENT Merko Ehitus sales revenue in the first quarter was EUR 68.4 million and net profit EUR 3.0 million. The sales revenue for the 3 months of 2022...
-
Excellent progress on clinical programs Lyme Disease Vaccine Candidate VLA15 Further positive Phase 2 results reported, including first pediatric data Phase 3 expected to commence in the third...